查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血清学检测市场：2023年至2028年预测
市场调查报告书
商品编码
1410033

血清学检测市场：2023年至2028年预测

Serological Testing Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

血清学检测市场预计在预测期内将以 4.50% 的复合年增长率成长。

血清学测试是一种实验室测试，可分析血液样本以检测抗体（例如抗体）的存在，并提供有关人的免疫反应的有价值的资讯。血清学检测产业为医院、诊所、诊断实验室、血库和其他依赖此类检测的组织提供准确诊断、监测病患健康、确保输血安全等支持，我们回应医疗机构的需求。新医院和血库的建立不断增加，是扩大血清学检测市场规模的重要驱动因素。

血库建设的蓬勃发展正在推动血清学检测市场的成长。

血库进行血清学检测，以确保捐血的血液和血液製品的安全。这些测试有助于识别血液样本中是否存在特定抗体或抗原。血库负责进行血清学检测，筛检感染疾病的血液是否患有爱滋病毒、B型肝炎、C型肝炎、梅毒和其他输血感染疾病。

医院体力的提升是血清检测市场扩大的原动力。

医院使用血清学检测，因为它们提供有关患者免疫反应的重要资讯，并有助于准确诊断和监测各种疾病。医院依靠血清学检测来识别抗体、检测传染源、评估疫苗接种状况并确定免疫系统功能。医院血清学检测需求的增加是由于感染疾病流行的日益严重，并且随着医院的不断扩大，血清学检测的需求也会增加。根据美国医院协会统计，美国医院总数从2021年的6,090家医院增加到2023年的6129家医院。

不断增加的公共卫生倡议正在推动血清学检测市场的成长。

血清学测试由于能够识别血液样本中抗体的存在而在公共卫生测试中受到欢迎。世界各国政府正在投资测试​​基础设施、研发和筛检项目，以控制疾病爆发、监测人群免疫力并确保血液安全。需求加速成长。据世界卫生组织（WHO）称，美国2020年向世卫组织和联合国儿童基金会提供了8400万美元，用于加强全球监测、维护实验室网络、采购疫苗、向各国提供技术援助以及支持当地社区，发挥了重要作用在振兴中。

预计亚太地区将主导市场。

亚太地区预计将在血清学检测市场中占据重要份额，因为该地区正在经历医疗保健行业、基础设施开拓、医疗设施和技术进步的快速扩张。这种增长推动了对血清学检测作为重要诊断工具的需求。此外，政府对医疗保健政策和公共卫生宣传活动的投资进一步推动了亚太地区血清学检测产业的成长。例如，在2023-24年联邦预算中，卫生和家庭福利部分配的预算为8915.5亿卢比，比上年度2021-22年预算8620.065亿卢比增加了3.43%。

高成本限制了血清学检测市场的成长。

血清学检测的成本可能是其采用的主要障碍，特别是在医疗保健预算有限或报销系统无法充分涵盖这些检测的地区。当使用先进技术和多重检测时，这项挑战尤其明显，而这通常涉及高昂的成本。高检测成本是一个障碍，限制了血清学检测的获得并阻碍了其广泛使用，普及是在资源匮乏的环境中，预算限制在医疗保健决策中发挥关键作用。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章血清学检测市场：依检测类型

  • 介绍
  • 初级血清学检测
    • 酵素结合免疫吸附测定法 (ELISA)
    • 萤光抗体测定（IFAT）
    • 免疫测量（RIA）
  • 二次血清学检测
    • 凝集试验
    • 补体结合试验（CFT）
    • 沉淀试验
  • 血清中和试验（SNT）
    • 毒素抗毒素测试
    • 三级结合测试

第六章血清学检测市场：依应用分类

  • 介绍
  • 轮状病毒感染疾病
  • 肝炎
  • HIV
  • 内毒素
  • 治疗药物监测
  • 其他感染疾病

第七章血清学检测市场：依最终使用者分类

  • 介绍
  • 医院和诊所
  • 诊断实验室
  • 血库
  • 其他的

第八章血清学检测市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Serological Research Institute（SERI）（UK）
  • Chembio Diagnostics, Inc（US）
  • Cellex（US）
  • Randox Laboratories Ltd（UK）
  • Abbott（US）
  • Bio-Rad Laboratories Inc.（US）
  • BD（US）
  • Thermo Fisher Scientific Inc.（US）
  • Ortho Clinical Diagnostics（US）
  • Quest Diagnostics Incorporated（US）
简介目录
Product Code: KSI061615692

The serological testing market is estimated to grow at a CAGR of 4.50% during the forecast period.

Serological testing is a laboratory test that analyses a blood sample to detect the presence of antibodies or other substances, providing valuable information about a person's immune response. The serological testing industry caters to the needs of medical institutions such as hospitals, clinics, diagnostic laboratories, and blood banks that rely on such testing for accurate diagnoses, monitoring patient health, and ensuring the safety of blood transfusions. The growing establishment of new hospitals and blood banks play vital roles as prominent drivers in augmenting the serological testing market size.

Booming blood bank establishment bolsters the serological testing market growth.

Serological testing is done in blood banks to ensure the safety of donated blood and blood products. These tests help identify the presence of specific antibodies or antigens in the blood samples. Blood banks are responsible for conducting serological tests to screen donated blood for infectious diseases, such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible infections.

The rise in hospitals' strength drives the serological market expansion.

Serological testing is used in hospitals as it provides crucial information about a patient's immune response, aiding in accurate diagnoses and monitoring of various diseases. Hospitals rely on serological tests to identify antibodies, detect infectious agents, assess vaccination status, and determine immune system function. The increasing demand for serological testing in hospitals is driven by the growing prevalence of infectious diseases and as hospitals continue to expand, demand for serological testing rises. According to the American Hospital Association, the total number of hospitals in the United States experienced an increase in 2023, reaching 6,129, compared to the previous count of 6,090 hospitals in 2021.

An increase in public health initiatives drives the serological testing market growth.

Serological testing due to its ability to identify the presence of antibodies in blood samples is experiencing a boost in public health checkups. Governments worldwide are investing in testing infrastructure, research, and development, and screening programs to control disease outbreaks, monitor population immunity, and ensure blood safety which is accelerating the demand for serological testing. According to the World Health Organization, in 2020, the United States extended a significant contribution of $84 million to WHO and UNICEF which played a vital role in bolstering global surveillance, sustaining the laboratory network, procuring vaccines, providing technical assistance to countries, and fostering community mobilization efforts.

Asia-Pacific is estimated to dominate the market.

Asia-Pacific will hold a significant share of the serological testing market as the region is experiencing rapid expansion in its healthcare sector, infrastructure development, medical facilities, and technological advancements. This growth is fuelling the demand for serological testing as a critical diagnostic tool. Moreover, government investments in healthcare policies and public health campaigns further support the growth of the serological testing industry in Asia-Pacific. For instance, in the Union Budget 2023-24, the Ministry of Health and Family Welfare received an allocation of Rs. 89,155 crore representing a growth of 3.43% from the previous year's allocation of Rs. 86,200.65 crore in 2021-22.

High cost restrains the serological testing market growth.

The cost of serological tests can be a significant hindrance to their adoption, particularly in regions with limited healthcare budgets or where reimbursement systems do not adequately cover these tests. This challenge is particularly pronounced when advanced technologies or multiplex assays are used, as they often involve higher expenses. The high cost of testing acts as a barrier, limiting access to serological testing and preventing its widespread utilization, especially in resource-constrained settings where budgetary constraints play a crucial role in healthcare decision-making.

Key Developments

  • May 2020: Thermo Fisher Scientific Inc. revealed its plans to further expand its efforts in response to the COVID-19 pandemic through a collaboration with WuXi Diagnostics and Mayo Clinic. This collaboration aims to develop a comprehensive total antibodies test for COVID-19. The combined expertise of all three organizations, including the clinical evaluation and support provided by the Mayo Clinic, has been instrumental in the development of this new serology test. By leveraging their collective capabilities, Thermo Fisher Scientific, WuXi Diagnostics, and Mayo Clinic are working together to enhance diagnostic capabilities and contribute to the ongoing global response against COVID-19.
  • April 2020: Eurofins Technologies introduced a range of CE-IVD marked serologic products designed to detect antibodies in individuals who have been exposed to the SARS-CoV-2 virus, which causes COVID-19. These newly launched products provide reliable and validated testing solutions to assess the immune response in patients, aiding in the diagnosis, monitoring, and management of COVID-19 cases. Eurofins Technologies' expansion of its serologic product portfolio strengthens the global fight against the pandemic by enhancing the availability of accurate serological testing options for healthcare providers.
  • April 2020: Roche, a leading healthcare company, developed the Elecsys Anti-SARS-CoV-2 serology test, a cutting-edge diagnostic tool that enables the detection of antibodies against the SARS-CoV-2 virus, responsible for COVID-19. This innovative serology test plays a vital role in identifying individuals who have been exposed to the virus and assessing their immune response. By determining the presence of antibodies, healthcare professionals can gain insights into a person's potential immunity against COVID-19, aiding in treatment decisions and providing valuable information for public health strategies.
  • March 2020: BD (Becton, Dickinson, and Company), a renowned global medical technology company, unveiled the Rapid Serology Test, an innovative point-of-care test that swiftly detects antibodies in blood to confirm recent or prior exposure to COVID-19. This breakthrough test provides results within a mere 15 minutes, enabling healthcare professionals to swiftly diagnose and determine the immune response of individuals. BD's introduction of the Rapid Serology Test strengthens the fight against the pandemic by offering a rapid and efficient serological testing solution.

Segmentation

By Test Type

  • Primary Serological Tests
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Immunofluorescent Antibody Technique (IFAT)
  • Radio Immunoassay (RIA)
  • Secondary Serological Tests
  • Agglutination Tests
  • Complement Fixation Tests (CFT)
  • Precipitation Tests
  • Serum Neutralization Tests (SNT)
  • Toxin-antitoxin Tests
  • Tertiary Binding Tests

By Application

  • Rotavirus
  • Hepatitis
  • HIV
  • Endotoxins
  • Therapeutic Drug Monitoring
  • Other Infectious Diseases

By End-Users

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Blood Banks
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SEROLOGICAL TESTING MARKET, BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Primary Serological Tests
    • 5.2.1. Enzyme Linked Immunosorbent Assay (ELISA)
    • 5.2.2. Immunofluorescent Antibody Technique (IFAT)
    • 5.2.3. Radio Immunoassay (RIA)
  • 5.3. Secondary Serological Tests
    • 5.3.1. Agglutination Tests
    • 5.3.2. Complement Fixation Tests (CFT)
    • 5.3.3. Precipitation Tests
  • 5.4. Serum Neutralization Tests (SNT)
    • 5.4.1. Toxin-antitoxin Tests
    • 5.4.2. Tertiary Binding Tests

6. SEROLOGICAL TESTING MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Rotavirus Infections
  • 6.3. Hepatitis
  • 6.4. HIV
  • 6.5. Endotoxins
  • 6.6. Therapeutic Drug Monitoring
  • 6.7. Other Infectious Diseases

7. SEROLOGICAL TESTING MARKET, BY END USERS

  • 7.1. Introduction
  • 7.2. Hospital and Clinics
  • 7.3. Diagnostic Laboratories
  • 7.4. Blood Banks
  • 7.5. Diagnostic Laboratories
  • 7.6. Others

8. SEROLOGICAL TESTING MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Serological Research Institute (SERI) (U.K.)
  • 10.2. Chembio Diagnostics, Inc (U.S.)
  • 10.3. Cellex (U.S.)
  • 10.4. Randox Laboratories Ltd (U.K.)
  • 10.5. Abbott (U.S.)
  • 10.6. Bio-Rad Laboratories Inc. (U.S.)
  • 10.7. BD (U.S.)
  • 10.8. Thermo Fisher Scientific Inc. (U.S.)
  • 10.9. Ortho Clinical Diagnostics (U.S.)
  • 10.10. Quest Diagnostics Incorporated (U.S.)